Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Organogenesis Holdings Inc’s stock clocked out at $5.04, down -6.84% from its previous closing price of $5.41. In other words, the price has decreased by -$6.84 from its previous closing price. On the day, 1.91 million shares were traded.
Ratios:
To gain a deeper understanding of ORGO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 152.92. For the most recent quarter (mrq), Quick Ratio is recorded 3.35 and its Current Ratio is at 3.69. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Lake Street on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5.
On February 07, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.Morgan Stanley initiated its Equal-Weight rating on June 15, 2023, with a $5 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 13 ’24 when Gillheeney Gary S. sold 55,615 shares for $3.36 per share. The transaction valued at 186,866 led to the insider holds 3,044,779 shares of the business.
Gillheeney Gary S. sold 5,585 shares of ORGO for $19,492 on Dec 16 ’24. The President and CEO now owns 3,039,194 shares after completing the transaction at $3.49 per share. On Dec 11 ’24, another insider, Gillheeney Gary S., who serves as the President and CEO of the company, sold 157,448 shares for $3.64 each. As a result, the insider received 573,111 and left with 3,143,753 shares of the company.
Valuation Measures:
As of this moment, Organogenesis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 900.00, and their Forward P/E ratio for the next fiscal year is 32.17. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.33 while its Price-to-Book (P/B) ratio in mrq is 2.41.
Stock Price History:
Over the past 52 weeks, ORGO has reached a high of $6.71, while it has fallen to a 52-week low of $2.16. The 50-Day Moving Average of the stock is 44.44%, while the 200-Day Moving Average is calculated to be 61.97%.
Shares Statistics:
A total of 125.73M shares are outstanding, with a floating share count of 64.36M. Insiders hold about 49.26% of the company’s shares, while institutions hold 49.46% stake in the company.
